This article was downloaded by:

On: 27 January 2011

Access details: Access Details: Free Access

Publisher Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-

41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information: http://www.informaworld.com/smpp/title~content=t713597286

Studies on the Chemical Synthesis of Potential Antimetabolites. 36. Synthesis and Some Biochemical Properties of (±)1-Deazaaristeromycin

Hiroaki Ohno^a; Tokuo Itoh^a; Akihiko Nomura^a; Yoshihisa Mizuno^a

^a Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo 060, Japan

To cite this Article Ohno, Hiroaki , Itoh, Tokuo , Nomura, Akihiko and Mizuno, Yoshihisa(1984) 'Studies on the Chemical Synthesis of Potential Antimetabolites. 36. Synthesis and Some Biochemical Properties of (\pm) 1-Deazaaristeromycin', Nucleosides, Nucleotides and Nucleic Acids, 3: 4, 345 — 351

To link to this Article: DOI: 10.1080/07328318408081273 URL: http://dx.doi.org/10.1080/07328318408081273

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

STUDIES ON THE CHEMICAL SYNTHESIS OF POTENTIAL ANTIMETABOLITES. 36. SYNTHESIS AND SOME BIOCHEMICAL PROPERTIES OF (±)1-DEAZAARISTEROMYCIN

Hiroaki Ohno, Tokuo Itoh*, Akihiko Nomura, and Yoshihisa Mizuno

Faculty of Pharmaceutical Sciences, Hokkaido University
Sapporo 060, Japan

Abstract — Chemical synthesis of a carbocyclic nucleoside, (\pm) 1-deaza-aristeromycin $(\underline{1})$, is described. Compound $\underline{1}$ was found to possess only a weak inhibitory effect on calf intestine adenosine deaminase. For rabbit liver S-adenosylhomocysteinase $\underline{1}$ showed weak affinity but acted as a potent irreversible inactivator.

<u>S</u>-Adenosylhomocysteinase (SAHase, EC 3.3.1.1) catalyzes reversible hydrolysis of <u>S</u>-adenosylhomocysteine (SAH) to adenosine and homocysteine. SAH is known to be a potent product inhibitor of <u>S</u>-adenosylmethionine-dependent methylation reactions involving nucleic acids, proteins, and phospholipids. Inhibition of SAHase may lead to an increase of SAH concentration, thereby perturbing <u>in vivo</u> methylation reactions.

The involvement of methyl transfer reactions in a variety of biological phenomena points to the possibility that inhibition of these reactions may be responsible for the pharmacological action of certain compounds. For example, it has been known that the antiviral agents 3-deazaadenosine and 9- β - $\underline{\mathbb{D}}$ -arabinofuranosyladenine (AraA) are potent inhibitors of SAHase. Thus, the concept of SAHase as a target for antiviral action of adenosine analogues has recently emerged 2

The findings that carbocyclic nucleosides $(\pm)3$ -deazaaristeromycin³ (2) and neplanocin A^{4,5} exhibit potent inhibitory activities for SAHases as well as a broad spectrum of antiviral activities prompt us to prepare an additional carbocyclic analogue, $(\pm)1$ -deazaaristeromycin $(\underline{1})$.

Synthesis of $\underline{1}$ was performed analogously according to the method for the preparation of 9-hydroxyethyl-1-deazaadenine⁶. Thus, 4-amino-2-chloro-3-nitropyridine⁷ ($\underline{3}$) was coupled with ($\underline{+}$)4 β -amino-2 α ,3 α -dihydroxy-1 β -cyclopentanemethanol ($\underline{4a}$), prepared by a slight modification of Saksena's procedure⁸, to give compound $\underline{5a}$ in 46 % yield. Catalytic hydrogenation over Raney nickel gave the corresponding triaminopyridine derivative ($\underline{6a}$), which was subjected to cyclization with formamidine acetate to afford $\underline{1}$ in 46 % yield based on $\underline{5a}$. The ultraviolet absorption spectrum of $\underline{1}$ was superimposable with 1-deazaadenosine^{6,9} and pmr spectral pattern due to the carbocyclic hydrogens was quite similar to that of aristeromycin. The overall yield was, however, comparatively low ($\underline{4a}$ through to $\underline{1}$, 21 %) because of the difficulty of purification of the intermediates ($\underline{4a}$ through to $\underline{6a}$ in Fig. 1). In order to overcome this problem, an isopropylidene derivative of the cyclopentane methanol ($\underline{4b}$) was chosen as an amine component in place of $\underline{4a}$.

A series of reactions (4b through to 7) proceeded much smoothly and 2^{+} , 3^{+} -0-isopropylidene-(\pm)1-deazaaristeromycin (7) was converted to 1 by treatment with aqueous formic acid. The overall yield was improved to some extent (29%).

Preliminary Evaluation of Biochemical Properties

Compound $\underline{1}$ was tested for its ability to inhibit calf intestine adenosine deaminase and rabbit liver SAHase 10 . Compound $\underline{1}$ was found to be a weak competitive inhibitor with a $\underline{K} i$ value of 140 μM for the adenosine deaminase 11 , while 1-deazaadenosine has been reported to be a competitive inhibitor with a $\underline{K} i$ value of 2 μM^{11b} . Aristeromycin has been known to act as a substrate with a $\underline{K} m$ value of 3.3 mM, showing less affinity to the enzyme compared with adenosine (Km 36 μM) 12 . These

Fig. 1. Preparation of (±)1-Deazaaristeromycin (1)

findings suggest that the replacement of the ribose moiety with a carbocyclic counterpart may weaken the affinity to the adenosine deaminase.

For the rabbit liver SAHase, $\underline{1}$ showed no significant affinity with a $\underline{K}i$ value of 530 μM but may act as a potent irreversible inactivator with a \underline{k} value 13 of 1.1 x 10^4 M $^{-1}$ min $^{-1}$. In contrast, compound $\underline{2}$ has been shown to be a competitive inhibitor with $\underline{K}i$ values of 3 μM and 1 nM for the enzyme from calf liver and hamster liver, respectively, but does not inactivate to any extent 3a . (±)Aristeromycin is reported to act as an inhibitor for calf liver SAHase both in a competitive 14 and an irreversible manner 13b . It is worthy of note that the isosteric carbocyclic deazanucleosides closely related to aristeromycin exhibit such a sharp dif-

348 OHNO ET AL.

ference in terms of interactions with SAHases. Details of the enzymological results using optically active 1-deazaaristeromycin will be the subject of a forthcoming paper.

EXPERIMENTAL

Melting points were determined with a Yamato melting point apparatus, type, MP-1, and are uncorrected. Ultraviolet absorption spectra were taken on a Hitachi 323 recording spectrophotometer. Pmr spectra were obtained on a JEOL FX-100 and FX-200 spectrometers using tetramethylsilane as an internal standard. Signals are designated as s (singlet), bs (broad singlet), d (doublet), t (triplet), and m (multiplet). Mass spectra were taken on a JEOL JMS-D300 mass spectrometer.

$(\pm)4\beta-(4-Amino-3-nitro-2-pyridylamino)-2\alpha$, $3\alpha-dihydroxy-1\beta-cyclopentane$ methanol (5a)

A mixture of (±)4 β -amino-2 α , 3 α -dihydroxy-1 β -cyclopentanemethanol (4 α , 163 mg, 1.1 mmol) and 4-amino-2-chloro-3-nitropyridine (3, 210 mg, 1.2 mmol) in absolute nitromethane (5 ml) containing triethylamine (0.3 ml) was refluxed for 5 h. After cooling the mixture to room temperature, precipitated yellow material was filtered and washed with water. Recrystallization from water gave $\frac{5a}{6}$ (140 mg, 44 % based on $\frac{4a}{6}$) in a pure state, mp 224° MS ($\frac{m}{2}$): 284 ($\frac{m}{4}$), 267, 249. Pmr in DMSO-d₆ (δ in ppm): 1.12 (m, 1H,H-5'a), 1.95 (m, 1H, H-4'), 2.28 (m, 1H, H-5'b), 3.40 (m, 2H, H-6'), 3.72 (m, 2H, H-2' and H-3'), 4.35 (m, 2H, H-1' and OH), 4.64 (t, 1H, OH), 4.87 (m, 1H, OH), 6.10 (d, 1H, H-5, J = 5.9 Hz), 7.63 (d, 1H, H-6, J = 5.9 Hz), 8.13 (bs, 2H, NH₂), 8.80 (bd, 1H, NH).

Anal. Calcd for $C_{11}^{H}_{16}^{N}_{4}^{O}_{5}$: C, 46.48; H, 5.67; N, 19.71. Found: C, 46.30; H, 5.67; N, 19.71.

2',3'-0-Isopropylidene derivative (5b) of 5a

A mixture of the isopropylidene derivative of 4a (4b, 98 mg, 0.52 mmol) and 3 (108 mg, 0.62 mmol) in absolute nitromethane (5 ml) containing triethylamine (0.1 ml) was refluxed for 5 h. Triethylamine hydrochloride, precipitated, was filtered off and the filtrate was evaporated in vacuo to give a syrup, which was chromatographed over a silica gel column (1.2 cm x 20 cm) with chloroform-methanol (50 : 1) as an eluent to give 5b (127 mg, 75 % based on 4b) as a yellow foam. MS (m/z): 324

 (M^{+}) , 309, 266, 235. Pmr in DMSO-d₆ (δ in ppm): 1.21 and 1.39 (each s, each 3H, 2 x CH₃), 1.51 (m, 1H, H-5'a), 2.15 (m, 1H, H-4'), 2.38 (m, 1H, H-5'b), 3.46 (m, 2H, H-6'), 4.40 - 4.69 (m, 3H, H-1', H-2', and H-3'), 5.00 (bs, 1H, OH), 6.12 (d, 1H, H-5, J = 5.9 Hz), 7.67 (d, 1H, H-6, J = 5.9 Hz), 8.31 (bs, 2H, NH₂), 8.96 (bd, 1H, NH, J = 7.3 Hz).

$(\pm)2',3'-0$ -Isopropylidene-l-deazaaristeromycin (7)

Compound 5b (290 mg, 0.89 mmol) in ethanol (10 ml) was stirred in the presence of Raney nickel (ca. 50 mg) under a hydrogen atmosphere until the yellow color of the mixture disappeared. The catalyst was filtered off and the solvent was evaporated to give a triamino-derivative (6b) as a colorless syrup. A mixture of 6b and formamidine acetate (151 mg, 1.3 mmol) in methoxyethanol (5 ml) was refluxed for 3 h under a nitrogen atmosphere. The reaction mixture was concentrated in vacuo to give a residue, which was chromatographed over a silica gel column with chloroform-ethanol (10:1) as an eluent to afford a crude sample of 7. Recrystallization from water gave 7 (225 mg, 83 % based on 5b), mp 89° (sintered). MS (10 m/z): 10 m/s, 10

Anal. Calcd for $C_{15}^{H}_{20}^{N}_{4}^{O}_{3}^{1}_{4}^{H}_{2}^{O}$: C, 53.33; H, 6.64; N, 18.14. Found: C, 58.44; H, 6.45; N, 17.90.

(±)1-Deazaaristeromycin (1)

(a) A suspension of $\underline{5a}$ (120 mg, 0.42 mmol) in methanol (15 ml) was stirred overnight with Raney nickel (\underline{ca} . 40 mg) under a hydrogen atmosphere at room temperature. The catalyst was filtered off and the filtrate was concentrated in vacuo to give a crude sample of $\underline{6a}$, which was used in the next step without further purification. A solution of $\underline{6a}$ and formamidine acetate (80 mg, 0.45 mmol) in methoxyethanol (5 ml) was refluxed for 2 h. Concentration of the reaction mixture left a residue, which was chromatographed over a Dowex 1 x 2 (OH form) column with 30 % aqueous methanol as an eluent to give a crude sample of $\underline{1}$. Recrystallization from water afforded $\underline{1}$ (51 mg. 46 %) in a pure state, mp 214° Uv $\lambda_{\rm max}^{\rm H_2O}$ (nm): ($\underline{\rm PH}$ 1), 265sh ($\underline{\rm cl1}$,800), 284 ($\underline{\rm cl6}$,400); ($\underline{\rm PH}$ 7) 264

350 OHNO ET AL.

(ϵ 13,300), 278sh (ϵ 11,000); (\underline{p} H 13) 264 (ϵ 13,800), 278sh (ϵ 10,800). MS ($\underline{m}/\underline{z}$): 264 (\underline{m}^+), 247, 233, 135, 134. Pmr in DMSO-d₆ (δ in ppm): 1.76 (m, 1H, H-5'a), 2.05 (m, 1H, H-4'), 2.21 (m, 1H, H-5'b), 3.48 (m, 2H, H-6'), 3.84 (m, 1H, H-3'), 4.37 (m, 1H, H-2'), 4.43 - 5.09 (m, 4H, H-1' and OH), 6.33 (m, 3H, NH₂ and H-1), 7.79 (d, 1H, H-2, J = 5.0 Hz), 8.11 (s, 1H, H-8).

Anal. Calcd. for $C_{12}H_{16}N_4O_3$: C, 54.52; H, 6.11; N, 21.20. Found: C, 54.29; H, 5.96; N, 21.12.

(b) A solution of <u>6b</u> (72 mg, 0.24 mmol) in 50 % formic acid (5 ml) was allowed to stand for 16 h at room temperature. Concentration of the reaction mixture gave a gray residue, which was crystallized from 7 % ammonium hydroxide to yield $\underline{1}$ (51 mg, 80 %). Physical properties of the sample agreed with those of $\underline{1}$ described above.

ACKNOWLEDGEMENT

We wish to thank Professor Tohru Ueda, Hokkaido University, for discussion. Thanks are also due to Dr. A. Saksena for providing us copies of pmr charts of some intermediates in the preparation of <u>4a</u>. We also thank the staff of the Analytical Center of Hokkaido University for their assistance with the analytical work.

REFERENCES AND NOTES

- 1. For 35; T. Itoh, T. Sugawara, A. Nomura, and Y. Mizuno, <u>Nucleosides</u> & <u>Nucleotides</u>, 1983, 2, 387.
- 2. For a leading review dealing with the topic; see P. M. Ueland, <u>Pharmacol. Rev.</u>, 1982, 34, 323.
- 3. a. J. A. Montgomery, S. J. Clayton, H. J. Thomas, W. M. Shannon, G. Arnet, A. J. Bodner, I.-K. Kion, G. L. Cantoni, and P. K. Chiang, J. Med. Chem., 1982, 25, 626. b. E. Clercq and J. A. Montgomery, Anti-viral Rev., 1983, 3, 17.
- 4. T. Ishikura, H. Nakamura, T. Sugawara, T. Itoh, A. Nomura, and Y. Mizuno, Nucleic Acids Res., Symp. Ser., No. 12., 1983, 119.
- R. T. Borchardt, B. T. Keller, and U. Patel-Thombre, <u>J. Biol. Chem.</u>, 1984, <u>259</u>, 4353.
- 6. T. Itoh, S. Kitano, and Y. Mizuno, J. Heterocycl. Chem., 1972, 9, 465.

- 7. J. A. Montgomery and K. Hewson, <u>J. Med. Chem.</u>, 1966, <u>9</u>, 105.
- 8. A. Saksena, Tetrahed. Lett., 1980, 21, 133.
- 9. T.Itoh, T. Sugawara, and Y. Mizuno, <u>Nucleosides & Nucleotides</u>, 1982, 1, 179.
- 10. Purification and properties of the enzyme will be published by our group.
- 11. <u>a.</u> The <u>Ki</u> value was determined according to Ikehara. <u>b.</u> M. Ikehara and T. Fukui, <u>Biochim. Biophys. Acta</u>, 1974, 338, 512.
- 12. L. Bennett, Jr., P. W. Allan, and D. L. Hill, <u>Mol. Pharmacol.</u>, 1967, <u>4</u>, 208.
- 13, <u>a</u>. The bimolecular rate constant (<u>k</u>) for the inactivation reaction was estimated according to Chiang 13b by the following equation:

$$\log P = 2 - \left(\frac{\underline{k \cdot I}}{2.303} t\right)$$

where P is the percentage activity remaining at the time t and \underline{I} is the inhibitor concentration. \underline{b} . P. K. Chiang, A. Guranowski, and J. E. Segall, Arch. Biochem. Biophys., 1981, 207, 175.

- 14. A. Guranowski, J. A. Montgomery, G. L. Cantoni, and P. K. Chiang, Biochemistry, 1981, 20, 110.
- 15. (\pm) 1-Deazaaristeromycin $(\underline{1})$ was tentatively numbered as shown below.

Received June 1, 1984